# Tome Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tome-biosciences

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.tome.bio
- Total disclosed funding: $213M
- Latest round: Series B (Dec 12, 2023)
- Investors on record: 7

## About

Based in the US and founded in 2021, Tome Biosciences, Inc. is a biotechnology firm that is developing programmable gene insertion technology. The company was co-founded by Omar Abudayyeh and Jonathan Gootenberg. In December 2023, Tome Biosciences Inc. raised USD 213 million in Series A and B funding investors Andreessen Horowitz, ARCH Venture Partners, Longwood Fund, Polaris Partners, Bruker Corporation, FUJIFILM Corporation, and Alexandria Venture Investments.

The company offers technologies that allow any genetic sequence of any size to be injected into any genome at any location using CRISPR. The firm is working on genomic therapeutics, delivering cures to patients through cell and genome engineering. The startup develops a variant of CRISPR that can insert 36,000 base pairs into the genome at once.

Tome Biosciences, Inc. will use the December 2023 funding to accelerate its genomic integration platform.

## Funding rounds

- Series B, Dec 12, 2023, $118M — Polaris Partners, Alexandria Venture Investments, Bruker Corporation, Fujifilm
- Series A, Jun 1, 2021, $95M — ARCH Venture Partners, Andreessen Horowitz, Longwood Fund

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Bruker Corporation — Series B
- Fujifilm — Series B